These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36896583)

  • 1. A Per-Protocol Analysis Using Inverse-Probability-of-Censoring Weights in a Randomized Trial of Initial Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Children.
    Yin DE; Cole SR; Ludema C; Brookhart MA; Golin CE; Miller WC; McKinney RE
    Am J Epidemiol; 2023 Jun; 192(6):916-928. PubMed ID: 36896583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
    Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE;
    PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial.
    Jespersen S; Hønge BL; Krarup H; Medstrand P; Sørensen A; Medina C; Té DDS; Correira FG; Erikstrup C; Østergaard L; Wejse C; Laursen AL;
    J Acquir Immune Defic Syndr; 2018 Nov; 79(3):386-393. PubMed ID: 30044302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.
    Borges ÁH; Lundh A; Tendal B; Bartlett JA; Clumeck N; Costagliola D; Daar ES; Echeverría P; Gisslén M; Huedo-Medina TB; Hughes MD; Huppler Hullsiek K; Khabo P; Komati S; Kumar P; Lockman S; MacArthur RD; Maggiolo F; Matteelli A; Miro JM; Oka S; Petoumenos K; Puls RL; Riddler SA; Sax PE; Sierra-Madero J; Torti C; Lundgren JD
    Clin Infect Dis; 2016 Jul; 63(2):268-80. PubMed ID: 27090986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
    Pasternak AO; Vroom J; Kootstra NA; Wit FW; de Bruin M; De Francesco D; Bakker M; Sabin CA; Winston A; Prins JM; Reiss P; Berkhout B;
    Elife; 2021 Aug; 10():. PubMed ID: 34387543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
    Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
    J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.